According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM ) is HK$27.87 Million. In 2023 the company made a revenue of HK$4.28 Million an increase over the revenue in the year 2022 that were of -HK$36.18 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.